|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Algeta ASA, of Oslo, Norway, said a paper showing the potential of its TH-1 technology for targeted cancer therapy was published in the journal Blood. Algeta's TH-1 technology links thorium-227, which emits alpha particles, to cancer-targeting molecules such as antibodies. The paper describes how researchers linked thorium-227 to the monoclonal antibody rituximab (Rituxan) to create 227Th-rituximab. It also included demonstrations of antitumor effects in vitro and in preclinical models.
o Derma Sciences Inc., of Princeton, N.J., obtained clearance from Health Canada to market and sell as Class II devices its line of API-MED Antimicrobial Dressings with Active ...